June 26, 2020 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the four-year results from the ILLUMENATE European Randomized Controlled Trial (EU RCT). The Stellarex DCB cohort demonstrated similar all-cause mortality compared with the control arm through four years. This analysis included […]
Author: Ken Dropiewski
JanOne taps distinguished chemist Dr. Doug Flanagan as chief formulation advisor
Dr. Flanagan, an accomplished chemist and formulation specialist, leads manufacturing and clinical development of JanOne’s PAD candidate TV1001SR LAS VEGAS, June 25, 2020 /PRNewswire/ — JanOne Inc. (NASDAQ: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive pain relieving properties, continues to build […]
NeuroMetrix Signs DPNCheck® Collaboration Agreement with Biomedix
WOBURN, Mass., June 25, 2020 (GLOBE NEWSWIRE) — NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it has signed a collaboration agreement with Biomedix to comarket DPNCheck for peripheral neuropathy detection within Medicare Advantage and other value-based care markets. NeuroMetrix and Biomedix provide complementary diagnostic tests to physicians and health plans. […]
New Late-Breaking Data Highlight Impact of Abbott’s Minimally Invasive Structural Heart Therapies
– New data reinforce Abbott’s leadership in minimally invasive treatment options for mitral and tricuspid repair and replacement therapies – Eleven late-breaking presentations at the PCR e-Course showcase impact of Abbott’s innovative structural heart portfolio on patient outcomes and quality of life in real-world and clinical settings ABBOTT PARK, Ill., June […]
Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule
VANCOUVER and MINNEAPOLIS, June 25, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), announced that it received written notification yesterday (the “Nasdaq Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the minimum market value requirement set […]
Espero BioPharma Assets Offered For Sale
NEW YORK, June 25, 2020 /PRNewswire/ — Espero BioPharma, Inc. is focused on the development of drugs for the treatment of cardiorenal diseases. The company, a private Delaware corporation, is the result of a 2017 business combination between Espero Pharmaceuticals, Inc. and Armetheon, Inc. The company’s portfolio of products includes: (i) tecarfarin, a Phase […]
Sequana Medical announces listing of 644,287 existing shares on Euronext Brussels following January 2020 Equity Placement
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW PRESS RELEASE 25 JUNE 2020 07:00 CEST REGULATED INFORMATION Ghent, BELGIUM – 25 June 2020 – Sequana […]
CHF Solutions Promotes Nestor Jaramillo, Jr. to President and Chief Operating Officer
EDEN PRAIRIE, Minn., June 25, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to improving the lives of patients suffering from fluid overload, today announced the promotion of Nestor Jaramillo, Jr. to President and Chief Operating Officer, effective July 1, 2020. In his expanded role, […]
InspireMD Announces Late-Breaking Presentation of Early SIBERIA Clinical Trial Results to be Featured in an e-Course at EuroPCR
In a head-to-head evaluation, significantly fewer silent brain infarcts were associated with CGuard™ EPS versus Acculink™ at 30 days post-procedure TEL AVIV, Israel, June 25, 2020 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid […]
NeuroMetrix Signs DPNCheck® Collaboration Agreement with Biomedix
WOBURN, Mass., June 25, 2020 (GLOBE NEWSWIRE) — NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it has signed a collaboration agreement with Biomedix to comarket DPNCheck for peripheral neuropathy detection within Medicare Advantage and other value-based care markets. NeuroMetrix and Biomedix provide complementary diagnostic tests to physicians and health plans. […]



